PHIO Logo

Phio Pharmaceuticals Corp. (PHIO) 

NASDAQ$1.29
Market Cap
$6.16M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
400 of 924
Rank in Industry
234 of 527

PHIO Insider Trading Activity

PHIO Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$1,4902100
Sells
$000

Related Transactions

Bitterman Robert JPresident & CEO2$1,4900$0$1,490

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that â€¦

Insider Activity of Phio Pharmaceuticals Corp.

Over the last 12 months, insiders at Phio Pharmaceuticals Corp. have bought $1,490 and sold $0 worth of Phio Pharmaceuticals Corp. stock.

On average, over the past 5 years, insiders at Phio Pharmaceuticals Corp. have bought $10,671 and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Bitterman Robert J (President & CEO) — $1,490.

The last purchase of 1,000 shares for transaction amount of $740 was made by Bitterman Robert J (President & CEO) on 2024‑06‑07.

List of Insider Buy and Sell Transactions, Phio Pharmaceuticals Corp.

2024-06-07PurchaseBitterman Robert JPresident & CEO
1,000
0.0216%
$0.74$740-58.12%
2024-06-06PurchaseBitterman Robert JPresident & CEO
1,000
0.0218%
$0.75$750-58.37%
2024-02-26PurchaseBitterman Robert JPresident & CEO
2,500
0.0539%
$0.91$2,275-60.89%
2023-07-01PurchaseBitterman Robert JPresident & CEO
1,000
0.0866%
$2.84$2,840-48.79%
2023-06-30PurchaseBitterman Robert JPresident & CEO
1,000
0.0879%
$2.88$2,880-67.89%
2023-06-14PurchaseFerrara Robert Ldirector
2,000
0.1723%
$3.10$6,200-69.59%
2022-12-14PurchaseBitterman Robert JInterim Executive Chairman
2,000
0.015%
$0.39$780-34.24%
2022-12-07PurchaseBitterman Robert JInterim Executive Chairman
2,000
0.0149%
$0.39$780-31.77%
2022-12-05PurchaseBitterman Robert JInterim Executive Chairman
2,000
0.0156%
$0.43$860-34.98%
2022-12-02PurchaseFerrara Robert Ldirector
5,000
0.0377%
$0.41$2,041-32.25%
2022-11-29PurchaseBitterman Robert JInterim Executive Chairman
215
0.0016%
$0.40$86-31.88%
2022-11-25PurchaseBitterman Robert JInterim Executive Chairman
2,500
0.019%
$0.42$1,050-31.05%
2022-11-23PurchaseFerrara Robert Ldirector
2,000
0.0147%
$0.41$820-31.71%
2022-11-16PurchaseBitterman Robert JInterim Executive Chairman
1
–
$1,750.00$1,750-30.57%
2021-08-16PurchaseDispersyn GerritPresident & CEO
6,000
0.0446%
$1.63$9,780-43.62%
2021-03-04PurchaseDispersyn GerritPresident & CEO
1,953
0.0185%
$2.56$5,000-26.88%
2021-03-03PurchaseDispersyn GerritPresident & CEO
2,500
0.0241%
$3.03$7,575-36.39%
2021-03-03PurchaseFerrara Robert Ldirector
682
0.0068%
$3.15$2,148-36.39%
2020-08-19PurchaseDispersyn GerritPresident & CEO
2,000
0.0345%
$2.50$5,000-8.96%
2017-10-02PurchaseCAUWENBERGH GEERTPresident & CEO
10,000
0.0428%
$0.45$4,475-35.40%
Total: 92
*Gray background shows transactions not older than one year
*Some uncertain data for Preferred Stock share type transactions are shown in italics; for actual data please follow the link

Insider Historical Profitability

<0.0001%
Bitterman Robert JPresident & CEO
20990
0.4394%
$27,077.10140<0.0001%
Advanced RNA Technologies, LLC
1221723
25.5759%
$1.58M10
CAUWENBERGH GEERTPresident & CEO
142583
2.9849%
$183,932.07600
Dispersyn GerritPresident & CEO
95281
1.9946%
$122,912.4950<0.0001%
Ferrara Robert Ldirector
6000
0.1256%
$7,740.0040<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$18,881,323
88
-48.96%
$4.47M
$1,159,104
40
-21.75%
$7.98M
$296,936
37
-18.12%
$4M
$523,320
24
94.37%
$7.01M
$31,129
22
-11.96%
$6.19M

PHIO Institutional Investors: Active Positions

Increased Positions9+150%151,171+530.31%
Decreased Positions2-33.33%25,631-89.91%
New Positions7New146,951New
Sold Out Positions2Sold Out25,631Sold Out
Total Postitions13+116.67%154,046+440.4%

PHIO Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Citadel Advisors Llc$63.000.89%44,526+44,526New2024-12-31
Hrt Financial Lp$60.000.85%42,338+42,338New2024-12-31
Virtu Financial Llc$58.000.82%40,910+40,910New2024-12-31
Cetera Investment Advisers$18.000.26%13,000+13,000New2024-12-31
Morgan Stanley$8.000.12%5,911+5,911New2024-12-31
Tower Research Capital Llc (Trc)$7.000.09%4,682+3,508+298.81%2024-12-31
Ubs Group Ag$3.000.05%2,397+712+42.26%2024-12-31
Barclays Plc$0<0.01%203+203New2024-12-31
Sbi Securities Co., Ltd.$0<0.01%63+63New2024-12-31
Activest Wealth Management$00%900%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.